Open Accessibility Menu

Multaq and Severe Liver Damage

Contact a Houston Dangerous Drug Lawyer to Discuss Your Case!

Multaq is a medication prescribed to help patients with an abnormal heartbeat. Its manufacturer, Sanofi-Aventis, reveals there have been at least 150 cases reported of liver damage to patients who took this anti-arrhythmic drug. Two of the Multaq liver damage cases were severe enough to require liver transplants.

The FDA will begin to require Multaq's drug label to warn of the risk of liver injury. The FDA issued a Drug Safety Alert for Multaq regarding the severe liver injuries that may happen with using Multaq. According to the FDA, "Dronedarone was approved with a Risk Evaluation and Mitigation Strategy (REMS) with a goal of preventing its use in patients with severe heart failure or who have recently been in the hospital for heart failure. In a study of patients with these conditions, patients given dronedarone had a greater than two-fold increase in risk of death." See the announcement from the FDA here.

Information about the potential risk of liver injury from dronedarone is being added to the WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections of the dronedarone labels. Sanofi-Aventis marketed Multaq as a better alternative to amiodarone, a medication associated with serious liver and lung injury in its users. Now the question is whether Multaq actually was safer than the cheaper, older drug it was meant to replace.

Danger of Liver Damage

Sanofi-Aventis recently admitted to the federal Food and Drug Administration (the FDA) that the company received many reports of liver injury and liver failure in individuals taking Multaq.

Signs of liver damage from Multaq may include:

  • Nausea
  • Vomiting
  • Loss of appetite
  • Pain or discomfort in the upper right area of the stomach
  • Yellowing (known as jaundice) of the skin or whites of the eyes
  • Darker urine
  • Itching

Other less serious side effects that have been reported with Multaq include rashes, stomach pain, slower heartbeat, breathing difficulty and rapid weight gain.

Anyone who believes they are showing signs of liver damage related to Multaq should contact their doctor immediately. It is critical that no prescription be discontinued without consulting with a doctor to discuss the risks involved.

Did you take Multaq and suffer a liver injury? Call our trial lawyers now.

Multaq was first sold in the United States in July 2009 to treat abnormal heartbeats. Close to 150,000 people have taken this drug and if you are one of them and you have suffered liver damage, our attorneys at Fibich, Leebron, Copeland & Briggs are available to discuss your injury and the possibility that you may be owed money damages from the maker of Multaq.

If you choose to have a legal evaluation of your use of Multaq and your health problems, we can provide a free confidential consultation. Our Houston personal injury attorneys are familiar with the issues concerning the Multaq cases and the kind of resources you may require during your recovery.

Contact our team of Houston dangerous drug lawyers at (713) 999-3681.

We Get Results

Understanding how to present the case in a way that best resonates with the jury is something that we know, and it's not something that anybody else knows as well.

Meet Your Relentless Legal Advocates

Our Attorneys Know What it Takes to Win
A Commanding Presence in the Courtroom Backed by a Longstanding Record of Success
  • $6,600,000.00 Catastrophic Injuries

    Attorneys Russ Briggs & Greg Fibich secured a $6.6 million dollar jury verdict on behalf of a client who suffered permanent medical issues after two doctors were found liable for failing to diagnose and treat a blood clot that developed after a surgical procedure.

We Will Give You a Voice

We handle complex cases across the nation. Get our nationally recognized trial lawyers on your side today.
  • Please enter your name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
  • Please make a selection.
  • Please enter a message.